UK shareholder meetings calendar - next 7 days
5th Nov 2025 14:25
(Alliance News) - Biotech Growth Trust PLC on Wednesday said Jenny Harries has been appointed an independent non-executive director, as of Tuesday. Read More
Biotech Growth Trust PLC - biotechnology-focused investor - Says capital reduction to become effective upon the registration of a court order from the High Court at Companies House. The firm says the purpose of the capital reduction is to provide a "significant pool of reserves" which can be used in future to fund share buybacks or other returns of capital. "The cancellation will therefore provide the company with more flexibility in how capital may be returned in the future," the company says. Read More
Biotech Growth Trust PLC - biotechnology-focused investor - Non-Executive Director Roger Yates buys 10,000 shares at 747.36 pence each, worth GBP74,736, on Wednesday. Earlier on Wednesday, the company said its net asset value declined during its most recent financial year, as market volatility weighs on investor appetite. Net asset value per share at March 31 was 815.9 pence, down 24% from 1,078.9p a year before. NAV total return for the year that ended March 31 was negative 24%, compared to a negative 6.0% return on its benchmark index, the Nasdaq Biotechnology Index. Read More
(Alliance News) - Biotech Growth Trust PLC on Wednesday said its net asset value declined during its most recent financial year, as market volatility weighs on investor appetite. Read More
(Alliance News) - Biotech Growth Trust PLC on Wednesday said biotech firms have shown "remarkable resilliance" as the firm highlighted the varied impact of macroeconomic factors on its half-year trading. Read More
(Alliance News) - Biotech Growth Trust PLC on Wednesday said it was relieved to see signs of recovery in the biotechnology sector, as it outperformed its benchmark. Read More
(Correcting description of Henry Boot.) Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday. Read More
(Alliance News) - Stock prices in London opened higher on Wednesday, beating European peers as the general election campaign heated up, and on a PMI-heavy day. Read More
(Alliance News) - Stocks in London are set to open higher on Wednesday, ahead of a data-heavy day for several global economies. Read More
(Alliance News) - Biotech Growth Trust PLC on Thursday said its net asset value decreased with a negative return in its latest half year, lamenting the "challenging backdrop" for its particular portfolio. Read More
(Alliance News) - Biotech Growth Trust on Thursday said its net asset value per share declined during financial 2023 and produced a negative return, with its chair saying the performance was "disappointing" though added that various "potential catalysts" could spark the sector's recovery. Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday. Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Herald Investment Trust PLC - London-based investment firm - Announces appointment of Biotech Growth Trust PLC Chair Andrew Joy as chair designate from October 1. Joy is set to replace current Chair Tom Black after firm's annual general meeting in April 2023. Black has served nearly ten years and "will work closely with Andrew to ensure an orderly transition," company says. Joy has been chair of Biotech Growth Trust, a London-based investor in global biotechnology companies, since July 2016, a role he will retire from next month. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and not separately reported by Alliance News: Read More
Biotech Growth Trust PLC - London-based investor in global biotechnology companies - Net asset value per share at March 31, end of financial year, falls 34% to 957.8 pence from 1,446.4p a year ago. Nasdaq Biotechnology Index, its benchmark, fell 7.4% during period. Biotech Growth underperformed benchmark. "Following the very strong results of the previous year, this has been a difficult year for the company," says Chair Andrew Joy. Read More